EXACT SCIENCES CORP (EXAS) Cash & Equivalents (2010 - 2025)

Exact Sciences (EXAS) has reported Cash & Equivalents for 16 consecutive years, with $956.0 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Cash & Equivalents rose 59.1% year-over-year to $956.0 million; the TTM figure through Dec 2025 stood at $956.0 million (up 59.1% YoY), while the FY2025 annual figure was $956.0 million, up 59.1% from the prior year.
• Cash & Equivalents rose to $956.0 million in Q4 2025 per EXAS's latest filing, from $7.3 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $1.1 billion in Q1 2021 and bottomed at $6.1 million in Q1 2025.
• Historically, Cash & Equivalents has averaged $442.9 million across 5 years, with a median of $392.5 million in 2021.
• Annual changes were most pronounced in 2023 — Cash & Equivalents jumped 183.18% — and 2025, when it slumped 98.76%.
• Exact Sciences' Cash & Equivalents stood at $315.5 million in 2021, then dropped by 23.13% to $242.5 million in 2022, then jumped by 149.65% to $605.4 million in 2023, then dropped by 0.74% to $600.9 million in 2024, then soared by 59.1% to $956.0 million in 2025.
• Business Quant data shows EXAS's Cash & Equivalents at $956.0 million in Q4 2025, $7.3 million in Q3 2025, and $657.1 million in Q2 2025.